In this session, we discuss current developments in monitoring and measurement technologies for clinical research and identify opportunities for optimizing the value of innovative technologies for medicines development and regulatory decision-making. The session will use a number of techniques and tools as an example (e.g. home sampling, wearable devices etc.), discuss pros and cons and explore the added value for future research. In particular, we will discuss the implications for regulatory and HTA evidence building with a special focus on the acceptability of evidence and the qualification of new methods.
14:30 – 14:45
Adoption of digital endpoints and telemedicine in clinical trials